NEW YORK (GenomeWeb News) – Opko Health has acquired Prost-Data, a Nashville, Tenn.-based CLIA laboratory doing business under the name OURLab.

Opko said that the acquisition would provide it with a commercial platform to support the US commercial launch of its 4Kscore protein biomarker prostate cancer test. The 4kscore test employs two protein biomarkers in the kallikrein family along with prostate-specific antigen for early detection of prostate cancer.

The lab has 18 phlebotomy sites throughout the US and a national sales force calling on urologists.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.